Nelson Owyoung, MD
Neurology · Alhambra, CANPI 1073543641
Payments from drug & device makers
Across 269 payments — averaging $28.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- AstraZeneca$705
- Neurocrine Biosciences, Inc.$679
- UCB, Inc.$440
- MDD US Operations, LLC$365
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$1061%
- Food & beverage$7,03192%
- Education$4666%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 85 | $1,777 |
| Teva Pharmaceuticals USA, Inc. | 27 | $1,071 |
| AstraZeneca(2 entities) | 14 | $705 |
| Neurocrine Biosciences, Inc. | 7 | $679 |
| UCB, Inc. | 39 | $440 |
| MDD US Operations, LLC | 11 | $365 |
| AbbVie(2 entities) | 18 | $279 |
| Livanova USA, Inc. | 4 | $253 |
| Sanofi-aventis U.S. LLC | 2 | $233 |
| Greenwich Biosciences, Inc. | 9 | $181 |
| Sunovion Pharmaceuticals Inc. | 4 | $151 |
| Pfizer | 8 | $142 |
| Amgen(2 entities) | 5 | $140 |
| Acadia Pharmaceuticals Inc | 2 | $131 |
| Lilly USA, LLC | 3 | $126 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $125 |
| Biohaven Pharmaceuticals, Inc. | 1 | $122 |
| Acorda Therapeutics, Inc | 5 | $106 |
| Avanir Pharmaceuticals, Inc. | 4 | $75 |
| Akcea Therapeutics, Inc. | 1 | $68 |
| Supernus Pharmaceuticals, Inc. | 4 | $60 |
| Eisai Inc. | 3 | $55 |
| Amneal Pharmaceuticals LLC | 2 | $45 |
| Aquestive Therapeutics, Inc. | 3 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Neurelis, Inc. | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Boston Scientific | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,603 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ApokynApomorphine Hcl | 16 | $246,991 |
| GocovriAmantadine Hcl | 76 | $153,271 |
| NuplazidPimavanserin Tartrate | 24 | $122,142 |
| BriviactBrivaracetam | 62 | $106,355 |
| RytaryCarbidopa/Levodopa | 79 | $90,124 |
| XcopriCenobamate | 55 | $71,608 |
| NuedextaDextromethorphan Hbr/Quinidine | 48 | $64,923 |
| OnfiClobazam | 21 | $54,560 |
| VimpatLacosamide | 41 | $45,869 |
| LamictalLamotrigine | 23 | $34,904 |
| AptiomEslicarbazepine Acetate | 25 | $33,536 |
| Zolmitriptan | 14 | $33,263 |
| Droxidopa | 14 | $33,020 |
| NeuproRotigotine | 17 | $19,248 |
| Oxtellar XrOxcarbazepine | 29 | $14,650 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Vimpat, Neupro | $440 | $171,472120 claims |
| MDD US Operations, LLCGocovri | $365 | $153,27176 claims |
| Acadia Pharmaceuticals IncNuplazid | $131 | $122,14224 claims |
| Amneal Pharmaceuticals LLCRytary | $45 | $90,12479 claims |
| SK Life Science, Inc.Xcopri | $1,777 | $71,60855 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $75 | $64,92348 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $151 | $33,53625 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $60 | $14,65029 claims |
| Neurocrine Biosciences, Inc.Ongentys | $679 | $14,24914 claims |
| PfizerEliquis | $142 | $12,42843 claims |
| AbbVieRestasis | $279 | $3,52011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,996 neurology providers in California.
Other neurology in Alhambra
- Timothy CloughesyLos Angeles$33.1M
- Jack FlorinFullerton$13M
- David KudrowSanta Monica$12.8M
- John Ravitsla Jolla$8.4M
- Perminder BhatiaFresno$8.3M
- Perry ShiehLos Angeles$8.2M
- Benjamin FrishbergCarlsbad$8.2M
- Bruce CreeSan Francisco$8M
- Lawrence RechtPalo Alto$6.6M
- Stanley PrusinerSan Francisco$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.